Breast Cancer: The Importance of Local Control

Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

Award-winning work by Dr. Marie Overgaard, of the Department of Oncology, Aarhus University Hospital, Denmark, gives new hope of longer survival for women with breast cancer. Dr. Overgaard’s work shows that treating the primary

Award-winning work by Dr. Marie Overgaard, of the Department of Oncology, Aarhus University Hospital, Denmark, gives new hope of longer survival for women with breast cancer. Dr. Overgaard’s work shows that treating the primary tumor with an optimal combination of surgery, radiotherapy and adjuvant chemotherapy markedly reduces the risk of local recurrences. Dr. Overgaard therefore calls for the reversal of current trends towards less aggressive local treatment for primary breast cancers.

Over the past 25 years, major improvements in survival from breast cancer have been achieved by giving adjuvant therapy,” said Dr. Overgaard at the 1997 European Cancer Conference. “But, paradoxically, there has been a tendency to treat the primary tumor less aggressively than before, on the basis that breast cancer is a systemic disease and that local treatment to the primary tumor will not affect survival.”

The Danish Breast Cancer Trials show that this view is mistaken. In these trials, 3,000 premenopausal and postmenopausal women received postmastectomy radiation and adjuvant systemic therapy, or systemic adjuvant therapy alone. Strikingly, during the 10-year follow-up period, the women who received systemic adjuvant therapy alone were four times more likely to develop local recurrences than the women who received combined therapy. 

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content